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Abstract
Objective
To identify the geographic, organisational, and payment correlates of buprenorphine and
methadone treatment among substance abuse treatment (SAT) providers.
Methods
Secondary analyses of the National Survey of Substance Abuse Treatment Services
(NSSATS) from 2007–16 were conducted. We provide bivariate descriptive statistics
regarding substance abuse treatment services which offered buprenorphine and metha-
done treatment from 2007–16. Using multiple logistic regression, we regressed geographic,
organisational, and payment correlates on buprenorphine and methadone treatment.
Results
Buprenorphine is increasingly offered at SAT facilities though uptake remains comparatively
low outside of the northeast. SAT facilities run by tribal governments or Indian Health Ser-
vice which offer buprenorphine remain low compared to privately operated SAT facilities
(AOR = 0.528). The odds of offering buprenorphine among facilities offering free or no
charge treatment (AOR = 0.838) or a sliding fee scale (AOR = 0.464) was lower. SAT facili-
ties accepting Medicaid payments showed higher odds of offering methadone treatment
(AOR = 2.035).
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Conclusions
Greater attention towards the disparities in provision of opioid agonist therapies is war-
ranted, especially towards the reasons why uptake has been moderate among civilian pro-
viders. Additionally, the care needs of Native Americans facing opioid-related use disorders
bears further scrutiny.
Introduction
The ongoing and sustained opioid epidemic in the United States has manifested as one of the
most urgent contemporary public health problems such that the United States Centers for Dis-
ease Control and Prevention (CDC) added the crisis to its list of the top five public health chal-
lenges in 2014 [1]. Opioid overdose deaths have increased at an alarming and accelerated rate;
from 2015–16, for instance, deaths due to opioid overdose increased 27.7% [2]. Opioid over-
dose mortality and its associated economic burden have been among the major consequences
of this epidemic; in 2014, for instance, 61% of drug overdose deaths involved opioids [3] while
health care spending among individuals with opioid abuse averages eight times higher than
individuals without opioid abuse [4].
The burden of the opioid epidemic, involving both the misuse of prescribed opioids and the
use of illicit opioids, has not manifested uniformly across the United States. One study found
that drug poisoning mortality and opioid consumption rates varied significantly by state and
region with drug poisoning rates highest in the Southwest and lowest in the Midwest [5].
Moreover, sales of opioid analgesic, which are prone to abuse, have varied significantly by state
as well, with Alaska showing a 13 times higher methadone distribution than Nebraska in 2002
[5]. Another study has found that prescription drug abuse of oxycodone has been unevenly
concentrated in eastern and southeastern states with a pattern of migration from the northeast
and Appalachia towards the southeast and west [6].
Despite the self-evident need for effective opioid misuse treatment, systemic barriers to
treatment persist [7, 8], particularly with respect to the type and mode of treatment [9, 10].
Because of the strict Federal regulatory oversight of pharmacotherapies for the treatment of
opioid misuse, the accessibility or lack thereof of treatments such as buprenorphine and meth-
adone has come under heightened scrutiny by researchers and practitioners [11] despite the
fact that the American Psychiatric Association (APA) has endorsed the use of pharmacother-
apy combined with psychotherapy as best practice [12, 13] and the American Society of Addic-
tion Medicine (ASAM) has established the use pharmacotherapy for the treatment of opioid
use disorder as a practice guideline [14]. Indeed, some practitioners have called for increased
access to buprenorphine in the outpatient setting [15]. In addition, as broader patterns of
macroeconomy have experienced a downturn at the start of the millennium, substance abuse
treatment providers have responded with respect to changes to patient mix by changes in pro-
vider operators and acceptance of private health insurance [16].
In this study, we make use of a routine, annual survey of all substance abuse treatment
(SAT) facilities in the United States to characterise the ways in which pharmacotherapeutic
approaches to managing opioid use disorders, specifically buprenorphine and methadone,
have or have not varied during ten recent years of the opioid epidemic from 2007–16, based
on geographic, operational, and payment characteristics. By doing so, we seek to describe
ongoing trends in SAT facility operations and whether or not disparities exist based on geo-
graphic, operational, and payment characteristics with respect to buprenorphine and
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methadone treatment, particularly given the clinical evidence supporting their use in opioid
abuse treatment [17]. Finally, we provide some recommendations for policymakers to address
issues facing the treatment of opioid use disorders based on our findings.
Methods
Our study used data from the 2007–16 waves of the National Survey of Substance Abuse Treat-
ment Services (N-SSATS), an annually repeated, survey of all known drug and alcohol abuse
treatment facilities, both public and private, in the United States [18–27]. Given that the
N-SSATS is a point-prevalence survey, where data is collected over a short, defined period of
time in contrast to a longitudinal study, facilities are surveyed year after year [18–27]. The
number of responses vary by year, with a minimum of 13,066 and a maximum of 14,162. The
average number of responses per year was 13,614. In our analysis, we make use of 136,143
responses from 2007–16. The N-SSATS collects data regarding the location and characteristics
of each substance abuse treatment (SAT) facility as well as the types of services offered [18–
27]. Data is collected through mailed questionnaires, telephone interviews, and web-based sur-
veys [18–27]. No adjustment is made for the approximately 5–10% facility nonresponse [18–
27].
N-SSATS respondent location was categorized using Census Bureau Divisions (“division”)
[28]: New England; Mid-Atlantic; East North Central; West North Central; South Atlantic;
East South Central; West South Central; Mountain; and Pacific. SAT facility operating entities
were defined as one of: private for-profit; private non-profit; state government; local govern-
ment; tribal government; Department of Veterans Affairs (VA); Department of Defense
(DoD); Indian Health Service (IHS); or other Federal agency [18–27]. SAT facility payment
characteristics were also obtained from the N-SSATS. Dichotomous variables were coded to
indicate whether a SAT facility provided no charge or free treatment, offered a sliding fee scale
to patients, accepted cash payments, accepted private insurance, accepted Medicare, accepted
Medicaid, accepted state (non-Medicaid) insurance, and accepted federal Military insurance
[18–27].
Our outcome variables of interest were dichotomous variables coded to indicate whether a
SAT facility offered specific pharmacotherapies: buprenorphine (with or without naltrexone)
and methadone [18–27]. For our analyses of SAT facilities offering methadone, only facilities
indicating the presence of an opioid treatment program (OTP) were assessed, as methadone
dispensing is strictly regulated by Federal regulations and limited to OTPs [29].
All statistical analyses were performed in Stata 14 [30]. Bivariate descriptive analyses were
conducted for our outcome variables of interest regarding service types and pharmacothera-
pies compared to facility characteristics, including geography, operating entity, and payment
characteristics as detailed above. Multiple maximum-likelihood logit regressions weighted
least squares were performed on these outcome variables, with and without adjustment, to
yield odds ratios associated with SAT facility characteristics, specifically, geography, operating
entity, and payment characteristics. The baseline characteristics used for logistic regressions
were: New England for division, private for-profit for operating entity, and the counterfactual
condition for payment characteristics (e.g. the counterfactual for “offers free or no charge
treatment” would be “does not offer free or no charge treatment”). In addition to adjustment
for our covariates of interest, all regression models also adjusted for year.
Results
Descriptive characteristics for our study population are shown in Table 1.
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As shown in Fig 1, the number of SAT facilities generally increased from 2007–16 across
divisions except for Pacific where a decline in the number of SAT facilities from 2008 is
observed. SAT facilities across all regions were mostly operated by private entities from 2007–
16, ranging from 86.5% of all surveyed SAT facilities in 2007 to 88.6% in 2016.
The percentage of SAT facilities offering buprenorphine increased from 2007–16 (χ2, nearly
doubling from 14.4% of all SAT facilities to 27.2%, across all divisions as shown in Fig 2; never-
theless, less than half of SAT facilities in New England and Mid-Atlantic, and South Atlantic
offered buprenorphine in 2016 and less than 25% did so in other divisions. Also shown in Fig
2, the percentage of SAT facilities buprenorphine increased from 2007–16 among SAT facili-
ties whose operating entities were private-for-profit, private non-profit, state government, and
Table 1. Characteristics of study population, 2007–16.
Year 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 χ2
n 13352 13404 13233 13066 13462 14056 13873 13914 13621 14162
Census Division p<0.001
New England 6.4% 6.5% 6.3% 6.3% 6.5% 6.7% 6.5% 6.6% 6.5% 6.8%
Mid-Atlantic 13.4% 13.7% 13.8% 14.2% 13.9% 13.2% 13.0% 13.2% 13.2% 12.8%
East North Central 15.8% 15.5% 15.3% 15.0% 15.1% 14.9% 15.1% 15.1% 14.9% 14.8%
West North Central 8.4% 8.3% 8.2% 8.6% 8.8% 8.8% 8.6% 8.9% 9.0% 9.0%
South Atlantic 15.6% 16.0% 16.0% 15.5% 15.8% 16.0% 16.4% 16.7% 17.0% 17.2%
East South Central 5.6% 5.4% 5.4% 5.6% 5.7% 5.9% 5.8% 5.7% 5.8% 5.8%
West South Central 6.8% 6.6% 6.6% 6.6% 6.5% 6.7% 6.8% 6.7% 6.5% 6.8%
Mountain 8.6% 8.9% 8.8% 9.3% 9.2% 9.9% 10.1% 10.0% 10.3% 10.4%
Pacific 19.4% 19.1% 19.6% 18.9% 18.6% 17.9% 17.6% 17.1% 16.8% 16.4%
Operating Entity p<0.001
Private-for-Profit 28.5% 29.3% 29.3% 30.0% 30.6% 31.1% 32.3% 33.0% 33.6% 35.4%
Private Non-Profit 58.0% 58.0% 57.9% 57.5% 57.3% 56.3% 55.3% 55.2% 54.6% 53.2%
State Government 3.1% 3.0% 2.9% 2.7% 2.4% 2.4% 2.3% 2.3% 2.4% 2.2%
Local, County, or Community Government 6.6% 6.1% 6.0% 5.7% 5.5% 5.4% 5.3% 5.1% 5.1% 5.0%
Tribal Government 1.4% 1.3% 1.4% 1.4% 1.6% 2.3% 2.1% 2.0% 1.9% 1.8%
Department of Veterans Affairs 1.4% 1.3% 1.6% 1.7% 1.7% 1.5% 1.6% 1.5% 1.5% 1.5%
Department of Defense 0.7% 0.7% 0.7% 0.7% 0.7% 0.6% 0.6% 0.6% 0.6% 0.6%
Indian Health Service 0.3% 0.3% 0.3% 0.3% 0.2% 0.4% 0.3% 0.2% 0.2% 0.2%
Other Federal Government Agency 0.1% <0.05% <0.05% <0.05% <0.05% <0.05% 0.1% 0.1% 0.1% <0.05%
Facility Characteristic
Operate an Opioid Treatment Program 8.3% 99.7% 99.7% 8.8% 8.8% 8.2% 9.2% 9.4% 9.8% 9.2% p<0.001
Types of Payment Assistance Offered
Offers no charge or free treatment 52.6% 52.1% 51.5% 49.6% 49.3% 49.5% 48.3% 47.1% 46.6% 45.5% p<0.001
Sliding fee scale 62.8% 62.9% 62.8% 62.6% 62.7% 62.2% 62.4% 61.4% 60.6% 59.6% p<0.001
Accepted Payment Types
Cash or Self-Payment 91.3% 90.1% 91.1% 91.5% 91.6% 90.7% 91.3% 90.8% 90.5% 90.4% p<0.001
Private Health Insurance 66.1% 64.7% 64.8% 65.8% 66.2% 66.8% 67.3% 68.7% 69.4% 70.5% p<0.001
Medicare 35.8% 35.9% 34.2% 33.9% 34.1% 34.6% 34.6% 34.6% 35.1% 35.6% p = 0.001
Medicaid 56.0% 55.5% 56.0% 57.0% 58.8% 60.3% 61.0% 62.1% 63.6% 63.8% p<0.001
State-Financed Health Insurance 37.5% 41.3% 41.1% 42.0% 42.0% 43.4% 44.4% 47.4% 48.4% 49.2% p<0.001
Federal Military Insurance 35.7% 35.4% 35.6% 35.5% 36.0% 36.5% 35.9% 36.7% 36.1% 36.5% p = 0.36
Pharmacotherapies Offered
Buprenorphine (with or without naloxone) 14.4% 15.2% 17.2% 18.6% 19.9% 20.7% 22.2% 23.4% 24.8% 27.2% p<0.001
Methadone 11.2% 8.4% 11.4% 11.5% 11.3% 11.3% 11.7% 11.8% 12.1% 12.5% p<0.001
https://doi.org/10.1371/journal.pone.0229787.t001
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Fig 1. Number of SAT Facilities by Census Bureau Division, 2007–16, and Percentage of SAT Facilities by Operating Entity by Census Bureau Division, 2007–16.
https://doi.org/10.1371/journal.pone.0229787.g001
Fig 2. Percentage of SAT Facilities Offering Buprenorphine by Census Bureau Division, 2007–16, and Percentage of SAT Facilities Offering Buprenorphine by
Operating Entity, 2007–16.
https://doi.org/10.1371/journal.pone.0229787.g002
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VA, markedly so in the latter case where buprenorphine was offered at approximately three-
quarters of SAT facilities operated by the VA in 2016. By contrast, less than 25% of SAT facili-
ties operated by tribal governments, DoD or IHS offered buprenorphine from 2007–16.
Overall, the number of SAT facilities which operated an OTP remained stable from 2007–
16, just below 10%. The number of SAT facilities which ran an OTP increased in South Atlan-
tic and remained relatively constant in most other divisions as shown in Fig 3. In Mid-Atlantic,
we observed an increase in the number of SAT facilities running an OTP in 2008, then declin-
ing until 2012 before increase again through to 2015. Reflecting broader patterns in facility
operation noted above, SAT facilities running an OTP were predominantly operated by private
entities.
Table 2 shows the results of unadjusted and adjusted results of logistic regression of geo-
graphic, operational, and payment characteristics associated with whether SAT facilities
offered buprenorphine and methadone pharmacotherapies from 2007–16. These results are
also shown graphically in Figs 4 and 5. SAT facilities in most divisions, except for Mid-Atlantic
(AOR: 1.15; 95% CI: 1.08–1.22), showed lower odds of offering buprenorphine treatment
when compared to New England. SAT facilities operated by private non-profit entities (AOR:
0.85; 95% CI: 0.82–0.88), local, county, or community governments (AOR: 0.71; 95% CI: 0.66–
0.77), tribal governments (AOR: 0.53; 95% CI: 0.45–0.62), or IHS (AOR: 0.65; 95% CI: 0.45–
0.95) showed lower odds of offering buprenorphine while those operated by state government
(AOR: 1.22; 95% CI: 1.11–1.35) or VA (AOR: 9.58; 95% CI: 8.40–10.93) showed higher odds of
offering buprenorphine. SAT facilities offering any type of payment assistance, either charity
care or a sliding fee scale, showed lower odds of offering buprenorphine than those that did
not offer any form of payment assistance. SAT facilities accepting cash or self-payment (AOR:
2.09; 95% CI: 1.94–2.25), private health insurance (AOR: 2.01; 95% CI: 1.93–2.25), Medicare
Fig 3. Number of SAT Facilities with OTPs by Census Bureau Division, 2007–16, and Percentage of SAT Facilities with OTPs Offering Methadone by Census
Bureau Division, 2007–16.
https://doi.org/10.1371/journal.pone.0229787.g003
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(AOR: 1.46; 95% CI: 1.40–1.52), or Medicaid (AOR: 1.09; 95% CI: 1.05–1.13) all showed higher
odds of offering buprenorphine than those not accepting.
For methadone treatment, different trends among geographic, operational, and payment
characteristics were found among SAT facilities operating an OTP. Compared to SAT facilities
in New England, SAT facilities in Pacific showed higher odds of offering methadone treatment
(AOR: 6.40; 95% CI: 2.93–13.98). Of the SAT facilities which responded to the N-SSATS from
2007–16, no SAT facilities operated by DoD ran an OTP and no SAT facilities operated by IHS
or another Federal government agency offered methadone treatment. SAT facilities operated
by a private non-profit entity (AOR: 0.57; 95% CI: 0.40–0.83) or by tribal government (AOR:
<0.01) showed lower odds of offering methadone treatment than SAT facilities operated by a
private-for-profit entity, particularly so in the latter case. SAT facilities accepting private health
Table 2. Unadjusted and adjusted multiple logistic regression of SAT facility characteristics associated with pharmacotherapies offered.
Buprenorphine Methadone�
Unadjusted Odds Raios Adjusted Odds Raios ��� Unadjusted Odds Raios Adjusted Odds Raios ���
Census Bureau Division
New England 1 1 1 1
Mid-Atlantic 1.051 (0.994–1.110) 1.147 (1.076–1.222) 0.981 (0.713–1.350) 0.621 (0.424–0.911)
East North Central 0.524 (0.494–0.555) 0.466 (0.437–0.498) 1.730 (1.132–2.642) 1.144 (0.702–1.864)
West North Central 0.336 (0.313–0.361) 0.278 (0.256–0.301) 2.993 (1.284–6.979) 3.979 (1.383–11.44)
South Atlantic 0.755 (0.715–0.797) 0.750 (0.704–0.799) 1.821 (1.266–2.621) 0.908 (0.583–1.415)
East South Central 0.354 (0.327–0.384) 0.320 (0.292–0.350) 2.566 (1.164–5.657) 0.882 (0.354–2.199)
West South Central 0.453 (0.421–0.486) 0.452 (0.416–0.491) 5.744 (2.614–12.62) 2.772 (0.999–7.692)
Mountain 0.551 (0.518–0.587) 0.559 (0.521–0.601) 2.298 (1.275–4.140) 1.661 (0.791–3.488)
Pacific 0.418 (0.395–0.442) 0.512 (0.479–0.548) 5.209 (2.945–9.214) 6.400 (2.929–13.98)
Operating Entity
Private-for-Profit 1 1 1 1
Private Non-Profit 0.704 (0.684–0.725) 0.849 (0.818–0.881) 0.292 (0.225–0.380) 0.574 (0.398–0.826)
State Government 0.954 (0.879–1.035) 1.223 (1.110–1.348) 0.322 (0.165–0.628) 0.475 (0.224–1.008)
Local, County, or Community Government 0.588 (0.550–0.628) 0.714 (0.660–0.772) 0.480 (0.260–0.885) 1.260 (0.542–2.928)
Tribal Government 0.374 (0.327–0.427) 0.528 (0.449–0.622) 0.0549 (0.0258–0.117) 0.00860 (0.00301–0.0246)
Department of Veterans Affairs 6.412 (5.836–7.045) 9.583 (8.403–10.93) 0.195 (0.121–0.313) 0.905 (0.432–1.893)
Department of Defense 0.466 (0.382–0.569) 1.319 (1.059–1.642) �� ��
Indian Health Service 0.350 (0.249–0.492) 0.653 (0.450–0.947) �� ��
Other Federal Government Agency 0.950 (0.523–1.726) 1.290 (0.661–2.519) �� ��
Types of Payment Assistance Offered
Offers no charge or free Tx 0.684 (0.666–0.702) 0.838 (0.809–0.867) 0.514 (0.411–0.643) 1.004 (0.740–1.360)
Uses sliding fee scale 0.568 (0.553–0.583) 0.464 (0.448–0.480) 0.674 (0.538–0.844) 0.994 (0.731–1.351)
Accepted Payment Types
Accepts cash or self-payment 1.838 (1.740–1.942) 2.085 (1.936–2.245) 1.838 (1.081–3.125) 2.009 (1.027–3.931)
Accepts private health insurance 2.269 (2.197–2.343) 2.012 (1.930–2.097) 0.114 (0.0791–0.165) 0.157 (0.101–0.245)
Accepts Medicare payments 1.646 (1.602–1.691) 1.458 (1.402–1.515) 0.304 (0.242–0.381) 0.696 (0.510–0.950)
Accepts Medicaid payments 1.291 (1.256–1.327) 1.088 (1.045–1.132) 0.521 (0.396–0.686) 2.035 (1.372–3.017)
Accepts state-financed health insurance 1.303 (1.268–1.339) 0.977 (0.941–1.015) 0.313 (0.246–0.398) 0.767 (0.557–1.055)
Accepts Federal military insurance 1.540 (1.497–1.583) 0.953 (0.917–0.990) 0.232 (0.183–0.294) 0.575 (0.426–0.776)
�Logistic regression was run only for facilities indicating a registered OTP
��No facilities operated by DoD, IHS, another Federal government agency indicated they registered OTP
��� Adjusted for year, geography, operating entity, and payment characteristics
https://doi.org/10.1371/journal.pone.0229787.t002
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insurance (AOR: 0.16; 95% CI: 0.10–0.25) and Medicare (AOR: 0.70; 95% CI: 0.51–0.95)
showed lower odds of offering methadone treatment than those that did not accept those
forms of payment while SAT facilities accepting Medicaid showed double the odds of offering
methadone treatment than SAT facilities not accepting Medicaid (AOR: 2.04; 95% CI: 1.37–
3.02).
Discussion
Our results showed changes in the SAT facility landscape from 2007–16 and highlighted differ-
ences in buprenorphine and methadone treatment availability based upon geographic, opera-
tional, and payment characteristics. Firstly, though it is promising to see that buprenorphine is
increasingly offered at SAT facilities among all divisions, uptake remained low outside of the
northeast; we observe that all regions, except for Mid-Atlantic, showed lower odds of SAT
facilities offering buprenorphine treatment. Moreover, though SAT facilities across a range of
operational entities increasingly offered buprenorphine treatment, the percentage of SAT facil-
ities run by tribal governments or IHS which offered buprenorphine remains low, highlighting
a potential disparity in treating Native Americans. Though SAT facilities operated by the VA
which offer buprenorphine have rapidly increased, growth has been more attenuated among
facilities run by other operational entities as shown by the odds of SAT facilities offering
buprenorphine among these SAT facilities. The odds of offering buprenorphine among facili-
ties offering payment assistance was lower than those without payment assistance. For metha-
done, on the other hand, we observed that SAT facilities accepting Medicaid payments showed
higher odds of offering methadone treatment.
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Fig 4. Unadjusted and adjusted effects on buprenorphine offering by SAT facility characteristics, 2007–16.
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Our analyses are limited by the shortcomings of data drawn from the N-SSATS. Given
major changes to survey design in 2007, namely the exclusion of questions capturing our inde-
pendent and dependent variables of interest, inclusion of prior waves of the N-SSATS which
could have extended our study period was not possible. Moreover, the N-SSATS does not col-
lect information regarding client mix among SAT facilities. As client mix and needs contribute
to the determination of individual SAT facility service offerings, this omission may have con-
tributed to omitted variables bias. Nevertheless, given that the N-SSATS is intended to be a
comprehensive annual survey of all SAT facilities in the United States, our analysis is strength-
ened as we can analyse nearly all SAT facilities rather than relying on a generalizable sample
[18–27]. Our use of a ten-year long study period further contributes to our attempts to mitigate
bias. In addition, to our knowledge, no other dataset currently exists which documents SAT
facilities on a national level to the extent that the N-SSATS provides.
Given the magnitude of the opioid epidemic and its sustained impact on population health,
our findings suggest that greater attention towards the provision of pharmacotherapies for the
treatment of opioid-related use disorders is warranted, such as understanding the reasons why
uptake of pharmacotherapies for the treatment of opioid-related use disorders has been mod-
erate among civilian healthcare providers. This can complement ongoing and sustained efforts
to alter prescribing practices [31] and to generate novel formulations of abuse-deterrent opioid
analgesics [32]. The relatively low numbers of civilian SAT facilities reporting the availability
of buprenorphine therapy is concerning, given research which suggests that drug-free treat-
ments may contribute towards greater patient mortality than medication-assisted therapy [33].
Though buprenorphine prescription has, to date, been strictly limited by law, researchers have
called on lawmakers to consider relaxing such restrictions as they may contribute to greater
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Fig 5. Unadjusted and adjusted effects on methadone offering by SAT facility characteristics (among SAT facilities
reporting an OTP), 2007–16.
https://doi.org/10.1371/journal.pone.0229787.g005
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patient harm [34]. Previous research has found a similar trend regarding the supply of waiv-
ered physicians in the northeast relative to other regions [35] and though some have offered
explanations for this with respect to health care reform [36] or regional variations in opioid
mortality [37], more research is needed to better understand the factors which have led to the
relatively low uptake of buprenorphine treatment outside of the northeast. A number of gen-
eral causes have been suggested as contributory towards the relatively low use of buprenor-
phine treatment, including a shortage of certified prescribers and worries about patient
diversion [38, 39] as well as insufficient prescriber knowledge about the use of opioid agonist
therapy and potential stigma associated with its use [40].
Our findings are consistent with other analyses of pharmacotherapy among providers pri-
marily focused on Native Americans which have also identified low rates of pharmacotherapy
implementation for substance abuse treatment [41]. In the case of opioids specifically, some
qualitative research suggests that the high prevalence of oxycodone use among a tribal commu-
nity has led to heightened sensitivity regarding opioid misuse [42], suggesting that approaches
to increasing the use of pharmacotherapy for opioid-related substance use disorders must be
culturally appropriate and contextual to the needs of Native Americans [43]. Developing cul-
tural competence and capacity for evidence-based treatment of opioid-related substance disor-
ders will contribute greatly to addressing the disparities we have identified.
With respect to methadone treatment, the relatively static number of SAT facilities with
OTPs over time may be cause for concern as the number of individuals with opioid-related use
disorders continues to increase. One study assessing the gap between treatment need and
capacity for OTPs found that 96% of states showed opioid abuse or dependence rates higher
than their OTP capacity rates with 38 states reporting at least 75% of their OTPs were operat-
ing at 80% capacity or more [11]. One way of addressing the lack of growth of OTPs is by
devoting greater resources towards expanding the number of waivered physicians who can
provide buprenorphine in the physician office setting, particularly among rural areas which
have been underserved with respect to opioid-related substance disorder treatment [44].
Another approach is to relax the patient limits set on waivered physicians which can be a less
resource-intensive method of increasing capacity for care without the need to increasing the
number of SAT facilities, OTP programs, or waivered physicians [45].
Opioid use disorder continues to present pressing and urgent challenges to public health.
SAT facilities, which serve a crucial role in the treatment of opioid use disorder, have generally
shown an increase in the use of buprenorphine yet this increase was not observed as strongly
among facilities offering payment assistance, a characteristic which may determine patient
access to treatment. Nevertheless, our observation that facilities accepting Medicaid payments
showed higher odds of offering methadone treatment suggests that there may be other oppor-
tunities where low-income, uninsured, or underinsured patients may receive medicated-assis-
tant treatment. Still, much more research is needed to understand how SAT facilities as a
whole, whether by policy or in practice, have responded to the opioid crisis. More nuanced
approaches to understanding local and regional contexts for opioid use disorders and their
treatment will enable more responsive care planning and service provision where it is needed
most, for instance, among areas with high populations of Native Americans.
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